TIMOPTIC
Pronunciation: TYE-moe-loel (tim-OP-tik)


What it isBeta-receptor antagonist eye drop that reduces aqueous production; open-angle glaucoma.
Why this oneThe benchmark ocular beta blocker, it is inexpensive and adds effectively to a prostaglandin analog.
What limits itEye drops can still cause bradycardia and bronchospasm; use punctal occlusion and avoid in asthma or heart block.
Animated chart of estimated U.S. prescriptions per year, Glaucoma medicines (1900–2026). Timolol enters in 1978 (estimated).
Principal riskSystemic beta blockade from eye drops: bradycardia and bronchospasm
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Elevated intraocular pressure (ocular hypertension, open-angle glaucoma) | Adults | 1 drop of 0.25% in affected eye(s) BID | 1 drop of 0.5% BID if response inadequate; may change to 1 drop QD once IOP controlled | 1 drop of 0.5% BID (higher doses add no IOP reduction) |
Titration Approximately 4 weeks (IOP response may take a few weeks to stabilize)
Renal Undefined
Hepatic Undefined
Systemically absorbed — beta-blocker class adverse reactions (bronchospasm, cardiac failure) can occur with eye drops.
Available strengths
Pregnancy No adequate human studies; no malformations in animals at high oral doses — use only if benefit justifies fetal risk.
Lactation Detected in human milk after oral and ophthalmic dosing; decide whether to discontinue nursing or the drug.
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.25 % | drops | per unit | not offered | |
| 0.5 % | drops | per unit | not offered |
Available combined with: dorzolamide / timolol
Generic entry2016
Open Timolol in the interactive console ↗

Open Timolol in the interactive console ↗